Lithium Versus Paroxetine in Major Depression

Major Depressive Disorder Clinical Trial

Official title:

A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01416220
• Other study ID #: MoodDig-001
• Status: Completed
• Phase: Phase 4
• Start date: September 2011
• Est. completion date: February 2013

Study information

• Verified date: July 2020
• Source: Nova Scotia Health Authority
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to look at how well people respond to two different drug treatments for depression. Clinically, people can respond differently to different treatments for reasons which are not always clear. Some research shows that people with a family history of bipolar disorder or completed suicide may react differently to standard medications used to treat depression than those without a family history. The investigators need to know if these drugs are effective to use in patients with depression who have a family history of bipolar disorder or completed suicide.

Description:

Lithium is a mood stabilizing drug that has been used to treat people with both bipolar disorder and depression for the last 50 years. It is available to the public by prescription in Canada and has been used by millions of people world wide. Paroxetine is an antidepressant drug that has been used to treat people with depression for the past 10 years. It is also available to the public by prescription in Canada and has been used by millions world wide.

Subjects who join the study, will be given one of the study drugs, either lithium or paroxetine.

Subjects will be randomized "like the flip of a coin" to receive either lithium or paroxetine.

The study drug will be taken once a day by mouth and the daily dose adjusted to find the right dose for the subject. The study drug will be taken for a 6-week period and subjects will be assessed by the research team on a weekly basis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• men or women

• age of 18 years or older

• meet criteria for major depressive episode, and have a family history of bipolar disorder or completed suicide

Exclusion Criteria:

• subjects not able to give informed consent

• pregnant or breast-feeding women

• current panic disorder, post traumatic stress disorder or psychosis

• subjects with a history of mania or hypomania

• subjects with active substance abuse or dependence in the last 6 months

• current depressive episode less than 4 weeks or greater than 12 months in duration

• adequate trial of lithium or paroxetine (lithium level = 0.6mmols/l; paroxetine 20mgs = 5 weeks) for this episode of depression

• concurrent use of other antidepressants or augmenting agents for the treatment of depression

• clinically significant medical illness, in particular renal impairment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Lithium
Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days. Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l.
• Paroxetine
Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days. Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.

Locations

Country	Name	City	State
Canada	Queen Elizabeth II Health Sciences Centre	Halifax	Nova Scotia

Sponsors (1)

Lead Sponsor	Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montgomery Asberg Depression Rating Scale (MADRS)	The primary outcome measure will be reduction in the score on the Montgomery Asberg Depression Rating Scale (MADRS), which has become the standard outcome tool in clinical trials for assessing symptoms of depression. Response will be defined as 50% reduction in MADRS Remission will be defined as MADRS = 12.	Assessed after 6 weeks of treatment
Secondary	The Young Mania Rating Scale (YMRS)	This is a standard outcome tool used to assess mania.	Assessed after 6 weeks of treatment
Secondary	The Clinical Global Impression (CGI)	The Clinical Global Impression (CGI)is a scale used to measure overall symptom severity, treatment response, and treatment efficacy in patients with mood disorders.	Assessed after 6 weeks of treatment
Secondary	The Columbia Suicide Classification Scale	The Columbia Suicide Classification Scale, used in the FDA analysis of pediatric antidepressants, has become a standard tool used in clinical depression trials and will be used to monitor changes in suicide risk or self-harm weekly.	Assessed over 6 weeks of treatment.
Secondary	Barnes Akathisia Rating Scale (BARS)	Barnes Akathisia Rating Scale (BARS): The BARS is a very brief clinical assessment for the presences of akathisia. Akathisia secondary to antidepressants has been associated with increased suicidality. The inclusion of the BARS will serve to delineate akathisia from psychomotor agitation as part of treatment -emergent mixed symptoms.	Assessed over 6 weeks of treatment
Secondary	Treatment -emergent symptom checklist and questionnaire	This checklist and questionnaire will be used to capture a potential range of treatment emergent mixed symptoms.	Assessed over 6 weeks of treatment